Finland· FI-REL-REL599
Potentol
A yohimbine product containing yohimbine hydrochloride + methyltestosterone + meprobamate, registered in Finland by Orion Corporation Orion Pharma. The same ATC class is registered in 4 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Yohimbine is registered in 4 of 19 countries.
Countries holding a registration under ATC G04BE04 (yohimbine), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 2 of them publish a price we can compare per daily dose
Yohimbine · ATC G04BE04
4 / 19 countries
- Belgiumprice
- Finlandprice
- Germany
- United Kingdom
The record
At a glance
Fimea (Finland)- Active substance
- Yohimbine hydrochloride + Methyltestosterone + Meprobamate
- Manufacturer
- Orion Corporation Orion Pharma
- Country
- Finland (FI)
- ATC code
- G04BE04
- ATC class
- Yohimbine
- Defined daily dose
- 15 mg, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
9 interactions on record for yohimbine.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Yohimbine · interactions on record
9 records
- 2 severe
- 5 moderate
- 2 minor
Most severe, free to view
- Iobenguane (123I)V09IX01severe
- Iobenguane (131I)V09IX02severe
- LorcaserinA08AA11moderate
- TroglitazoneA10BG01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under G04BE04
Yohimbine, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c237c734-a6d9-4dab-8854-2d30ee03a93e GET /v1/drugs/c237c734-a6d9-4dab-8854-2d30ee03a93e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "15",
"form": "tabletti",
"route": null,
"ddd_unit": "mg",
"strength": null,
"atc_label": "johimbiini",
"ma_number": "5218",
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": null,
"fimea_rel_id": "REL599",
"authorised_at": "1968-01-31"
}See everything about yohimbine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.